References
- 1. J. La Bonte, J. Lebbos, A. Raja and P. Kirkpatrick, Infectious Diseases, Nat. Rev. Drug Discov. 3 (2004) S26–S32; https://doi.org/10.1038/nrd1409
- 2. B. Hughes, Tapping into combination pills for HIV, Nat. Rev. Drug Discov. 8 (2009) 439–440; https://doi.org/10.1038/nrd2917
- 3. A. Raja, J. Lebbos and P. Kirkpatrick, Atazanavir sulphate, Nat. Rev. Drug Discov. 2 (2003) 857–858; https://doi.org/10.1038/nrd1232
- 4. K. Geetha Bhavani, K. Bala Murali Krishna, N. Srinivasu, D. Ramachandran, N. V. V. S. S Raman and B. Hari Babu, Determination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS, J. Pharm. Biomed. Anal. 132 (2017) 156–158; https://doi.org/10.1016/j.jpba.2016.09.025
- 5. K. Watanabe, E. Varesio and G. Hopfgartner, Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format, J. Chromatogr. B 965 (2014) 244–253; https://doi.org/10.1016/j.jchromb.2014.05.008
- 6. S. Colombo, N. Guignard, C. Marzolini, A. Telenti, J. Biollaz and L. A. Decosterd, Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction, J. Chromatogr. B 810 (2004) 25–34; https://doi.org/10.1016/j.jchromb.2004.07.008
- 7. A. Loregian, S. Pagni, E. Ballarin, E. Sinigalia, S. G. Parisi and G. Palù, Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection, J. Pharm. Biomed. Anal. 42 (2006) 500–505; https://doi.org/10.1016/j.jpba.2006.04.031
- 8. S. Dey, S. S. Patro, N. S. Babu, P. N. Murthy and S. K. Panda, Development and validation of a stability-indicating RP–HPLC method for estimation of atazanavir sulfate in bulk, J. Pharm. Anal. 7 (2017) 134–140; https://doi.org/10.1016/j.jpha.2013.12.002
- 9. C. H. Bhirud and S. N. Hiremath, Stability indicating RP-HPLC method for the determination of atazanavir sulphate in bulk and dosage form, Drug Invent. Today 5 (2013) 81–86; https://doi.org/10.1016/j.dit.2013.05.008
- 10. L. Else, V. Watson, J. Tjia, A. Hughes, M. Siccardi, S. Khoo and D. Back, Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds, J. Chromatogr. B 878 (2010) 1455–1465; https://doi.org/10.1016/j.jchromb.2010.03.036
- 11. M. Mirochnick, B. M. Best, A. M. Stek, E. V. Capparelli, C. Hu, S. K. Burchett, S. S. Rossi, E. Hawkins, M. Basar, E. Smith and J. S. Read, Atazanavir pharmacokinetics with and without tenofovir during pregnancy, JAIDS J. Acquir. Immune Defic. Syndr. 56 (2011) 412–419; https://doi.org/10.1097/QAI.0b013e31820fd093
- 12. S. Goutelle, T. Baudry, M.-C. Gagnieu, A. Boibieux, J.-M. Livrozet, D. Peyramond, C. Chidiac, M. Tod and T. Ferry (on behalf of the Lyon HIV Cohort Study Group), Pharmacokinetic-pharmaco-dynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients, Antimicrob. Agents Chemother. 57 (2013) 517–523; https://doi.org/10.1128/AAC.01822-12
- 13. C. S. Venuto, K. Mollan, Q. Ma, E. S. Daar, P. E. Sax, M. A. Fischl, A. C. Collier, K. Y. Smith, C. Tierney and G. D. Morse (on behalf of AIDS Clinical Trial Group Study A5202 Team), Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202, J. Antimicrob. Chemother. 69 (2014) 3300–3310; https://doi.org/10.1093/jac/dku303
- 14. D. K. Lloyd and J. Bergum, Application of quality by design (QbD) to the development and validation of analytical methods, in: Specification of Drug Substances and Products - Development and Validation of Analytical Methods (C. M. Riley, T. W. Rosanske and S. R. Rabel Riley, Eds.), Elsevier, Amsterdam 2014, pp. 29–72.
- 15. B. Kelley, M. Cromwell and J. Jerkins, Integration of QbD risk assessment tools and overall risk management, Biologicals 44 (2016) 341–351; https://doi.org/10.1016/j.biologicals.2016.06.001
- 16. P. K. Sahu, N. R. Ramisetti, T. Cecchi, S. Swain, C. S. Patro and J. Panda, An overview of experimental designs in HPLC method development and validation, J. Pharm. Biomed. Anal. 147 (2018) 590–611; https://doi.org/10.1016/j.jpba.2017.05.006
- 17. M. de Matas, T. De Beer, S. Folestad, J. Ketolainen, H. Lindén, J. A. Lopes, W. Oostra, M. Weimer, P. Öhrngren and J. Rantanen, Strategic framework for education and training in Quality by Design (QbD) and process analytical technology (PAT), Eur. J. Pharm. Sci. 90 (2016) 2–7; https://doi.org/10.1016/j.ejps.2016.04.024
- 18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Pharmaceutical Development Q8 (R2), Current Step 4 version, August 2009; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf; last access date March 10, 2018.
- 19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Quality Risk Management Q9, Current Step 4 version, November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf last access date March 10, 2018.
- 20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Pharmaceutical Quality System Q10, Current Step 4 version, June 2008; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf last access date March 10, 2018.
- 21. J. Kochling, W. Wu, Y. Hua, Q. Guan and J. Castaneda-Merced, A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC–MS methods development for protein analysis, J. Pharm. Biomed. Anal. 125 (2016) 130–139; https://doi.org/10.1016/j.jpba.2016.03.031
- 22. G. L. Reid, J. Morgado, K. Barnett, B. Harrington, J. Wang, J. Harwood and D. Fortin, Analytical Quality by Design (AQbD) in pharmaceutical development, Am. Pharm. Rev. 16 (2013); https://www.americanpharmaceuticalreview.com/Featured-Articles/144191-Analytical-Quality-by-Design-AQbD-in-Pharmaceutical-Development/; last access date December 26, 2018.
- 23. P. S. Sandhu, S. Beg, R. Kumar, O. P. Katare and B. Singh, Analytical QbD-based systematic bio-analytical HPLC method development for estimation of quercetin dihydrate, J. Liq. Chromatogr. Relat. Technol. 40 (2017) 506–516; https://doi.org/10.1080/10826076.2017.1329744
- 24. A. Dispas, H. T. Avohou, P. Lebrun, P. Hubert and C. Hubert, ‘Quality by Design’ approach for the analysis of impurities in pharmaceutical drug products and drug substances, Trends Anal. Chem. 101 (2017) 24–33; https://doi.org/10.1016/j.trac.2017.10.028
- 25. T. Schofield, D. Robbins and G. Miró-Quesada, Critical Quality Attributes, Specifications, and Control Strategy, in Quality by Design for Biopharmaceutical Drug Product Development (Eds. F. Jameel, S. Hershenson, M. A. Khan and S. Martin-Moe) /Advances in the Pharmaceutical Sciences Series, AAPS, Vol. 18 (Eds. D. J. A. Crommelin and R. A. Lipper)/Springer, New York, pp. 511–535.
- 26. U. S. Food and Drug Administration (FDA), Center for drug evaluation and research (CDER), Reviewer Guidance-Validation of Chromatographic Methods, November 1994; https://www.fda.gov/downloads/Drugs/Guidances/UCM134409.pdf; last access date December 26, 2018
- 27. What is peak tailing? Chromatogr. Today, August 8, 2014; https://www.chromatographytoday.com/news/autosamplers/36/breaking-news/what-is-peak-tailing/31253; last access date December 26, 2018.
- 28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Current Step 4 version, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date March 10, 2018.
- 29. T. Sharma, R. K. Khurana, A. Jain, O. P. Katare and B. Singh, Development of a validated liquid chromatographic method for quantification of sorafenib tosylate in the presence of stress-induced degradation products and in biological matrix employing analytical quality by design approach, Biomed. Chromatogr. 32 (2018) e4169; https://doi.org/10.1002/bmc.4169
- 30. N. K. Garg, G. Sharma, B. Singh, P. Nirbhavane and O. P. Katare, Quality by Design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate, J. Liq. Chromatogr. Relat. Technol. 38 (2015) 1629–1637; https://doi.org/10.1080/10826076.2015.1087409
- 31. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Stability Testing of New Drug Substances and Products Q1A(R2), Current Step 4 version, February 2003; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf; last access date March 10, 2018.
- 32. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Stability Testing: Photostability Testing of New Drug Substances and Products Q1B, Current Step 4 version, November 1996; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1B/Step4/Q1B_Guideline.pdf; last access date March 10, 2018.
- 33. L. Zhang and S. Mao, Application of quality by design in the current drug development, Asian J. Pharm. Sci. 12 (2017) 1–8; https://doi.org/10.1016/j.ajps.2016.07.006
- 34. A. Loregian, S. Pagni, E. Ballarin, E. Sinigalia, S. G. Parisi and G. Palù, Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection, J. Pharm. Biomed. Anal. 42 (2006) 500–505; https://doi.org/10.1016/j.jpba.2006.04.031
- 35. S. R. Chitturi, Y. S. Somannavar, B. G. Peruri, S. Nallapati, H. K. Sharma, S. R. Budidet, V. K. Handa and H. B. Vurimindi, Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate, J. Pharm. Biomed. Anal. 55 (2011) 31–47; https://doi.org/10.1016/j.jpba.2011.01.002
- 36. M. K. V. V. N. Mantripragada, S. V. Rao, V. V. S. Nutulapati and B. P. V. Mantena, Simultaneous determination of impurities of atazanavir and ritonavir in tablet dosage form by using reversed-phase ultra performance liquid chromatographic method, J. Chromatogr. Sci. 56 (2018) 270–284; https://doi.org/10.1093/chromsci/bmx110
- 37. N. Phung, K. Kuncze, H. Okochi, A. Louie, L. Z. Benet, I. Ofokotun, D. W. Haas, J. S. Currier, T. D. Chawana, A. N. Sheth, P. Bacchetti, M. Gandhi and H. Horng, Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom. 32 (2018) 431–441; https://doi.org/10.1002/rcm.8058